Unique ID issued by UMIN | UMIN000009778 |
---|---|
Receipt number | R000002157 |
Scientific Title | A prospective randomized study of "covered" vs "uncovered" metallic stents for the management of biliary stricture by unresectable pancreatic cancer. |
Date of disclosure of the study information | 2013/01/14 |
Last modified on | 2014/02/19 09:15:13 |
A prospective randomized study of "covered" vs "uncovered" metallic stents for the management of biliary stricture by unresectable pancreatic cancer.
"Covered" vs "uncovered" metallic stents for biliary stricture by unresectable pancreatic cancer.
A prospective randomized study of "covered" vs "uncovered" metallic stents for the management of biliary stricture by unresectable pancreatic cancer.
"Covered" vs "uncovered" metallic stents for biliary stricture by unresectable pancreatic cancer.
Japan |
Biliary stricture caused by unresectable pancreatic cancer
Hepato-biliary-pancreatic medicine |
Malignancy
NO
To evaluate the efficacy of covered metallic stent (CMS) and uncovered metallic stent (UMS)
Efficacy
Confirmatory
Pragmatic
Phase III
duration until stent dysfunction
1) overall survival
2) incidence of side effect
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Device,equipment |
Covered metallic stent (CMS)
Uncovered metallic stent (UMS)
Not applicable |
Not applicable |
Male and Female
1) Pancreatic head cancer with biliary stricture
2) Pathological confirmation is essential.
3) Stricture of bile duct is middle to lower common bile duct.
4) Clinical stage (UICC) is more than stage 2b.
5)Informed consent is essential.
1) PS > 4.
2) Severe complication of another organ.
3) A patient who gives no written IC.
4) A participating doctor thinks the patient is not proper for this study.
5) Prognosis will be within 3 months.
6) Initial drainage worsen the status of the patient.
120
1st name | |
Middle name | |
Last name | Hidekazu Mukai |
Yodogawa Christian Hospital
Department of Gastroenterology
Awaji 2-9-26, Higashiyodogawa-Ku, Osaka
06-6322-2250
1st name | |
Middle name | |
Last name | Kiyohito Tanaka |
Kyoto Second Red Cross Hospital
Department of Gastoroenterology
075-231-5171
Kansai Endoscopic Device Selection (EDS) Working Group
Kansai Endoscopic Device Selection (EDS) Working Group
Self funding
NO
2013 | Year | 01 | Month | 14 | Day |
Published
http://www.nature.com/ajg/journal/v108/n11/full/ajg2013305a.html
Patient survival time in the two groups did not signifi cantly differ (median: 285 and 223 days,
respectively; P = 0.68). Patient survival time without stent dysfunction was signifi cantly longer
in the covered than in the uncovered SEMS group (median: 187 vs. 132 days; P = 0.043).Stent patency was also signifi cantly longer in the covered than in the uncovered SEMS group
(mean +- s.d.: 219.3 +- 159.1 vs. 166.9 +- 124.9 days; P = 0.047).Rates of tumor overgrowth and sludge formation did not signifi
cantly differ between the two groups, whereas the rate of tumor ingrowth was signifi cantly lower
in the covered than in the uncovered SEMS group ( P < 0.01).There was no signifi cant difference between
the two groups in the incidence of serious adverse events.
Completed
2009 | Year | 02 | Month | 15 | Day |
2009 | Year | 04 | Month | 01 | Day |
2011 | Year | 09 | Month | 01 | Day |
2011 | Year | 12 | Month | 24 | Day |
2012 | Year | 02 | Month | 25 | Day |
2012 | Year | 03 | Month | 31 | Day |
2013 | Year | 01 | Month | 14 | Day |
2014 | Year | 02 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002157